Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 variants of concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer's disease.
Erickson MA, Logsdon AF, Rhea EM, Hansen KM, Holden SJ, Banks WA, Smith JL, German C, Farr SA, Morley JE, Weaver RR, Hirsch AJ, Kovac A, Kontsekova E, Baumann KK, Omer MA, Raber J. Erickson MA, et al. Among authors: kontsekova e. Brain Behav Immun. 2023 Mar;109:251-268. doi: 10.1016/j.bbi.2023.01.010. Epub 2023 Jan 20. Brain Behav Immun. 2023. PMID: 36682515 Free PMC article.
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217.
Kovacech B, Cullen NC, Novak P, Hanes J, Kontsekova E, Katina S, Parrak V, Fresser M, Vanbrabant J, Feldman HH, Winblad B, Stoops E, Vanmechelen E, Zilka N. Kovacech B, et al. Among authors: kontsekova e. Alzheimers Res Ther. 2024 Nov 23;16(1):254. doi: 10.1186/s13195-024-01620-7. Alzheimers Res Ther. 2024. PMID: 39580468 Free PMC article. Clinical Trial.
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial.
Cullen NC, Novak P, Tosun D, Kovacech B, Hanes J, Kontsekova E, Fresser M, Ropele S, Feldman HH, Schmidt R, Winblad B, Zilka N. Cullen NC, et al. Among authors: kontsekova e. EBioMedicine. 2024 Jan;99:104923. doi: 10.1016/j.ebiom.2023.104923. Epub 2023 Dec 14. EBioMedicine. 2024. PMID: 38101301 Free PMC article. Clinical Trial.
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B, Fialova L, Filipcik P, Skrabana R, Zilkova M, Paulenka-Ivanovova N, Kovac A, Palova D, Rolkova GP, Tomkova K, Csokova NT, Markova K, Skrabanova M, Sinska K, Basheer N, Majerova P, Hanes J, Parrak V, Prcina M, Cehlar O, Cente M, Piestansky J, Fresser M, Novak M, Slavikova M, Borsova K, Cabanova V, Brejova B, Vinař T, Nosek J, Klempa B, Eyer L, Hönig V, Palus M, Ruzek D, Vyhlidalova T, Strakova P, Mrazkova B, Zudova D, Koubkova G, Novosadova V, Prochazka J, Sedlacek R, Zilka N, Kontsekova E. Kovacech B, et al. Among authors: kontsekova e. EBioMedicine. 2022 Feb;76:103818. doi: 10.1016/j.ebiom.2022.103818. Epub 2022 Jan 22. EBioMedicine. 2022. PMID: 35078012 Free PMC article.
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease.
Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N. Novak P, et al. Among authors: kontsekova e. Nat Aging. 2021 Jun;1(6):521-534. doi: 10.1038/s43587-021-00070-2. Epub 2021 Jun 14. Nat Aging. 2021. PMID: 37117834 Clinical Trial.
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.
Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, Boonkamp L, Novak M, Zetterberg H, Hansson O, Scheltens P, Blennow K, Teunissen CE, Zilka N. Hanes J, et al. Among authors: kontsekova e. Neurology. 2020 Dec 1;95(22):e3026-e3035. doi: 10.1212/WNL.0000000000010814. Epub 2020 Sep 24. Neurology. 2020. PMID: 32973122 Free PMC article.
Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation.
Zilkova M, Nolle A, Kovacech B, Kontsekova E, Weisova P, Filipcik P, Skrabana R, Prcina M, Hromadka T, Cehlar O, Rolkova GP, Maderova D, Novak M, Zilka N, Hoozemans JJM. Zilkova M, et al. Among authors: kontsekova e. Acta Neuropathol Commun. 2020 May 29;8(1):74. doi: 10.1186/s40478-020-00948-z. Acta Neuropathol Commun. 2020. PMID: 32471486 Free PMC article.
Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans.
Weisová P, Cehlár O, Škrabana R, Žilková M, Filipčík P, Kováčech B, Prčina M, Wojčiaková Ľ, Fialová Ľ, Smolek T, Kontseková E, Žilka N, Novák M. Weisová P, et al. Among authors: kontsekova e. Acta Neuropathol Commun. 2019 Aug 7;7(1):129. doi: 10.1186/s40478-019-0770-y. Acta Neuropathol Commun. 2019. PMID: 31391090 Free PMC article.
73 results